Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With

Publication/Presentation Date

10-1-2022

Abstract

PURPOSE: The TAPUR Study is a pragmatic phase II basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from two cohorts of patients with colorectal cancer (CRC) with either

METHODS: Eligible patients with measurable CRC were selected for treatment with P + T according to protocol-specified genomic matching rules. Patients had no remaining standard treatment options, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Simon's two-stage design was used with a primary study end point of disease control (DC; objective response [OR] or stable disease of at least 16 weeks duration [SD16+]). Secondary end points include safety, response duration, progression-free survival (PFS), and overall survival (OS).

RESULTS: Thirty-eight patients with CRC with

CONCLUSION: Although P + T treatment does not appear to have antitumor activity in CRC with

Volume

6

First Page

2200306

Last Page

2200306

ISSN

2473-4284

Disciplines

Medicine and Health Sciences

PubMedID

36315917

Department(s)

Hematology-Medical Oncology Division, Department of Medicine

Document Type

Article

Share

COinS